Oncology: a new era in therapies; same cost concerns

The cliché of building an airplane while in flight might hold with today’s oncology market: new therapies are just on the horizon, while a host of issues around affordability, prescribing practices and reimbursement policies are shifting. Millions of patients are […]

Read More

Changing the payment paradigm

Oncology stands out in the debate over how drugs are priced and paid for in the US, although oncolytics are certainly not the only drugs getting this attention. Nevertheless, the cancer care community—oncologists and health administrators—have issued reports and recommendations […]

Read More
| 1 Comment